ISSN :2822-5872
Is plasminogen activator inhibitor-1 level a prognostic marker in COVID-19? [ACH Medical Journal]
ACH Medical Journal. 2024; 3(4): 137-145 | DOI: 10.5505/achmedj.2024.38233

Is plasminogen activator inhibitor-1 level a prognostic marker in COVID-19?

Güler İnönü1, Oguzhan Zengin1, Esra Fırat Oğuz2, Enes seyda Şahiner1, İhsan Ateş1
1Health Science University, Department of Internal Medicine, Ankara, Türkiye
2Ankara Bilkent City Hospital, Department Of Biochemistry, Ankara, Türkiye

INTRODUCTION: We aimed to investigate the relationship of plasminogen activator inhibitor-1 (PAI-1) level, which is the main inhibitor of the fibrinolytic system, with COVID – 19 severities.
METHODS: A total of 88 cases diagnosed with COVID – 19, 42 with mild pneumonia and 46 with severe pneumonia, were prospectively included in the study. Serum PAI-1 level was studied by ELISA method. COVID – 19 diagnosis was made by reverse transcriptase-polymerase chain reaction test.
RESULTS: PAI – 1 level was found to be higher in the group with severe pneumonia compared to the group with mild pneumonia (72.1 ng/mL vs 64.1 ng/mL, respectively; p=0.005). In the multivariate regression analysis high level of serum PAI – 1 was associated with severe pneumoniae (OR: 1.073; CI: 1.003 – 1.147; p=0.040). The cut off value of PAI – 1 for severe pneumoniae was determined as 65.8 ng/mL with 52.2% sensitivity, specificity of 78.6%, positive predictive value of 72.7% and negative predictive value of 60%. The patients whose PAI – 1 level were over 65.8 ng/mL were found to have 4.646 times increased risk of severe pneumoniae compared to the ones who had PAI – 1 lower than 65.8 ng/mL (OR: 4.646; CI: 1.186 – 18.202; p= 0.027).
DISCUSSION AND CONCLUSION: In this study, we found out that the serum level of PAI – 1 was higher in patients with severe pneumoniae than the ones with mild pneumoniae. High level of serum PAI – 1 was associated with severe pneumoniae.

Keywords: COVID-19, plasminogen activator inhibitor-1, prognostic marker in COVID-19

Corresponding Author: Güler İnönü, Türkiye
Manuscript Language: English
×
APA
NLM
AMA
MLA
Chicago
Copied!
CITE